Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

Novo Nordisk (NYSE: NVO) is under attack. Although the Denmark-based drugmaker is a pioneer and leader in the GLP-1 diabetes and weight loss drug markets, countless companies are trying to steal ...

The Food and Drug Administration on Tuesday approved Novo Nordisk's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular ...

While Novo Nordisk has established a strong position in metabolic disease with the GLP-1 agonist semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for obesity, the pharmaceutical ...

Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4 Becker’s contributions to the campaign, meanwhile, include Type 2 diabetes-friendly twists on recipes ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Shares of Novo Nordisk slipped ... overweight or obesity and type 2 diabetes," said Martin Holst Lange, executive vice president for development at Novo Nordisk. "We look forward to bringing ...

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... an adjunct to standard of care in 9,650 patients with type 2 diabetes and established cardiovascular disease and/or chronic ...

But what if Novo Nordisk could market a therapy that's even more effective than these two? Enter CagriSema, an investigational diabetes and obesity medicine the company is testing in phase 3 studies.